The management of osteoporosis in breast cancer survivors

Maturitas

Volumn 73, Issue 4, 2012, Pages 275-279

  Taxel, Pamela ^a   Choksi, Palak ^b   Van Poznak, Catherine ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bone health; Breast cancer; Osteoporosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; EXEMESTANE; LETROZOLE; METHOTREXATE; PLACEBO; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

AEROBIC EXERCISE; AMENORRHEA; BONE ATROPHY; BONE DENSITY; BONE TURNOVER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; COMORBIDITY; COMPUTER PROGRAM; DIETARY INTAKE; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; EXERCISE; FRACTURE; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; HUMAN; IDIOPATHIC HYPERCALCIURIA; OSTEOCLAST; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VITAMIN D DEFICIENCY;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS;

EID: 84869094245     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2012.08.009     Document Type: Review

References (49)

1. R. Siegel, C. DeSantis, and K. Virgo Cancer treatment and survivorship statistics, 2012 CA: A Cancer Journal for Clinicians 2012 doi:10. 3322/caac.21149
2. http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/ breast-cancer-key-statistics.
3. H.J. Burstein, A.A. Prestrud, and J. Seidenfeld American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer Journal of Clinical Oncology 28 2010 3784 3796
4. J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, and N. Khaltev The diagnosis of osteoporosis Journal of Bone and Mineral Research 9 1994 1137 1141
5. E.S. Siris, S.K. Brenneman, and E. Barrett-Connor The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA) Osteoporosis International 17 4 2006 565 574
6. http://www.nof.org.
7. Z. Chen, M. Maricic, and T.L. Bassford Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study Archives of Internal Medicine 165 2005 552 558
8. E.B. Lamont, and D.S. Lauderdale Low risk of hip fractures among elderly breast cancer survivors Annals of Epidemiology 12 2003 1 6
9. C. Van Poznak, and S. Sauter Clinical management of osteoporosis in women with a history of breast carcinoma Cancer 104 3 2005 443 456
10. J. Bines, D.M. Oleske, and M.A. Cobleigh Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer Journal of Clinical Oncology 14 May (5) 1996 1718 1729
11. N.C. Greep, A.E. Giuliano, N.M. Hansen, T. Taketani, H.J. Wang, and F.R. Singer The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer American Journal of Medicine 114 2003 653 659
12. C. Van Poznak, P.G. Morris, and G. D'Andrea Changes in bone mineral density (BMD) of postmenopausal women who are not receiving adjuvant endocrine therapy for breast cancer (BCA) Cancer Research 69 24 2009 559S:1066 [Abstract]
13. http://clinicaltrials.gov/ct2/show/NCT00603551.
14. T.J. Powles, T. Hickish, and J.A. Kanis Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women Journal of Clinical Oncology 14 1996 78 84
15. R.R. Love, R.B. Mazess, and H.S. Barden Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer The New England Journal of Medicine 326 March 1992 852 856
16. R.L. Ward, G. Morgan, D. Dalley, and P.J. Kelly Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women Bone and Mineral 22 August (2) 1993 87 94
17. B. Kristensen, B. Ejlertsen, and P. Dalgaard Tamoxifen and bone metabolism in postmenopausal lowrisk breast cancer patients: a randomized study Journal of Clinical Oncology 12 1994 992 997
18. A. Resch, E. Biber, M. Seifert, and H. Resch Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer Acta Oncologica 37 7-8 1998 661 664
19. L. Vehmanen, I. Elomaa, C. Blomqvist, and T. Saarto Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status Journal of Clinical Oncology 24 February (4) 2006 675 680
20. R.E. Coleman, L.M. Banks, and S.I. Girgis Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study The Lancet Oncology 8 February (2) 2007 119 127
21. M. Rabaglio, Z. Sun, and K.N. Price BIG 1-98 Collaborative and International Breast Cancer Study Groups Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial Annals of Oncology 20 September (9) 2009 1489 1498
22. A. Buzdar, A. Howell, and J. Cuzick Arimidex, tamoxifen, alone or in combination trialists' group comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial The Lancet Oncology 7 August (8) 2006 633 643
23. R. Eastell, J.E. Adams, and R.E. Coleman Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230 Journal of Clinical Oncology 26 March (7) 2008 1051 1057
24. P.E. Lonning, J. Geisler, and L.E. Krag Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer Journal of Clinical Oncology 23 August (22) 2005 5126 5137
25. B.E. Hillner, J.N. Ingle, and R.T. Chlebowski American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer Journal of Clinical Oncology 21 November (21) 2003 4042 4057
26. J.R. Gralow, J.S. Biermann, and A. Farooki NCCN Task Force Report: Bone Health in Cancer Care Journal of the National Comprehensive Cancer Network 7 Suppl. 3 2009 S1 S32
27. http://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/ osteors.htm.
28. J.A. Kanis, A. Oden, and O. Johnell The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporosis International 18 August (8) 2007 1033 1046
29. D.M. Reid, J. Doughty, and R. Eastell Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group Cancer Treatment Reviews 34 Suppl. 1 2008 S3 S18
30. P. Hadji, M. Hartenfels, J. Kyvernitakis, O. Hars, K.H. Baumann, and M. Kalder Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES) Breast Cancer Research and Treatment 133 June (3) 2012 1089 1096
31. G.B. Mann, Y.C. Kang, C. Brand, P.R. Ebeling, and J.A. Miller Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance Journal of Clinical Oncology 27 August (22) 2009 3605 3610
32. P.M. Camacho, A.S. Dayal, and J.L. Diaz Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis Journal of Clinical Oncology 26 November (33) 2008 5380 5385 [Epub 27 October 2008]
33. A.L. Schwartz, K. Winters-Stone, and B. Gallucci Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy Oncology Nursing Forum 34 May (3) 2007 627 633
34. K.K. Swenson, M.J. Nissen, E. Anderson, A. Shapiro, J. Schousboe, and J. Leach Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy The Journal of Supportive Oncology 7 May-June (3) 2009 101 107
35. K.M. Winters-Stone, A.L. Schwartz, S.C. Hayes, C.J. Fabian, and K.L.A. Campbell prospective model of care for breast cancer rehabilitation: bone health and arthralgias Cancer 118 April (8 Suppl.) 2012 2288 2299
36. N.L. Waltman, J.J. Twiss, and C.D. Ott The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial Osteoporosis International 21 2010 1361 1369
37. P. Hadji, M. Gnant, and J.J. Body Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treatment Reviews 38 October (6) 2012 798 806
38. J.E. Lester, D. Dodwell, and O.P. Purohit Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer Clinical Cancer Research 14 October (19) 2008 6336 6342
39. C. Van Poznak, R.A. Hannon, and J.R. Mackey Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE Trial Journal of Clinical Oncology 28 6 2010 967 975
40. C. Markopoulos, E. Tzoracoleftherakis, and A. Polychronis Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial Breast Cancer Research 12 2 2010 R24
41. A. Grey, M.J. Bolland, and A. Horne Five years of anti-resorptive activity after a single dose of zoledronate - results from a randomized double-blind placebo-controlled trial Bone 50 June (6) 2012 1389 1393
42. A. Valachis, N.P. Polyzos, V. Georgoulias, D. Mavroudis, and D. Mauri Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis Gynecologic Oncology 117 April (1) 2010 139 145
43. K. Ito, V.S. Blinder, and E.B. Elkin Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer Journal of Clinical Oncology 30 May (13) 2012 1468 1475
44. J.J. Body Prevention and treatment of side-effects of systemic treatment: bone loss Annals of Oncology 21 Suppl. 7 2010 vii180 vii185
45. G.K. Ellis, H.G. Bone, and R. Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer Journal of Clinical Oncology 26 October (30) 2008 4875 4882
46. N. Pavlakis, R. Schmidt, and M. Stockler Bisphosphonates for breast cancer Cochrane Database Syst Rev 2005 CD003474
47. http://clinicaltrials.gov/ct2/show/NCT00127205.
48. http://clinicaltrials.gov/ct2/show/NCT01077154.
49. P. Hadji, J.J. Body, and M. Aapro Practical guidance for the management of aromatase inhibitor-associated bone loss Annals of Oncology 19 2008 1407 1416